Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Poll

July 18, 2011

Clinical Trial Strategy

Unlike large biopharma firms, most small biotech companies usually have their fortunes riding on only a single drug. If a small firm’s product fails a Phase II trial, do you think the smart move is to keep working on its product candidate instead of entirely scrapping the project?

If a firm’s only candidate fails a Phase II trial, should it push on with development?

  {{ choice.Percent }}%